Why FMCG Giants Are Buying Nutraceutical Brands Instead of Building Them

India's nutraceutical market is now worth close to $9 billion, and depending on whose forecast you trust, it's on track to hit somewhere between $23 billion and $30 billion within the next six to eight years. That kind of growth usually triggers a predictable response from large FMCG players: build a competing product, lean on distribution muscle, and out-scale the smaller brands.

That's not what's happening this time.

Instead, some of India's largest FMCG companies have been acquiring nutraceutical and wellness brands rather than building competing products from scratch. It's a small but telling shift, and it says something important about where the real value sits in this category and what founders building in this space should be optimizing for.

Distribution used to be the moat. It isn't anymore.

For decades, the FMCG playbook worked because distribution was the hard part. If you could get a product onto more shelves than your competitor, you won, regardless of whether your product was meaningfully better. Manufacturing scale and retail relationships were the moat.

Nutraceuticals break that model. A consumer buying a supplement isn't just buying a product; they're buying a bet on efficacy and safety, often for their own or a family member's health. That bet is built on trust, and trust doesn't scale the way distribution does. You can't manufacture credibility at volume the way you can manufacture capsules.

This is precisely why acquisition has become the faster path for large players. Buying an already-trusted brand skips the years it would take to build that trust organically and, in a category, growing this fast, speed matters more than margin efficiency.

What this means if you're building a nutraceutical brand right now

If distribution and manufacturing scale are no longer the defensible asset, the natural next question is: what is?

The honest answer is that the accumulated, hard-to-fake sequence of a real customer using your product, having a good outcome, telling someone, and coming back for a repeat purchase, is the asset. That's not something a large player can shortcut by writing a bigger check for factory capacity. It's the reason acquisition, not replication, has become the strategy.

This reframes a few decisions founders in this space are making right now:

Formulation choices should optimize for defensibility, not just cost. A generic formulation that's easy for anyone to replicate is a weaker long-term asset than a differentiated one built on proprietary sourcing, standardized extracts, or clinical backing, even if it costs more to produce.

Positioning needs to build toward a category, not just a product. Brands that come to own a specific health outcome in the consumer's mind (a particular ingredient, a particular use case, a particular life stage) are harder to displace and more attractive to an acquirer than brands selling an undifferentiated "wellness" story.

Retention data is now a strategic asset, not just an operating metric. If trust and repeat behavior are what's actually being acquired, then a brand's retention curve is effectively evidence of that trust. Founders should be tracking and improving it with the same seriousness they'd apply to CAC.

The two businesses hiding inside one company

Every nutraceutical founder is, whether they realize it or not, building two overlapping businesses at once: a product business (formulation, manufacturing, margin) and a brand business (positioning, trust, retention). The market is currently placing a premium on the second one.

That doesn't mean product quality doesn't matter, obviously it does, and it's the foundation everything else is built on. But founders who treat brand-building and retention as secondary to manufacturing efficiency are optimizing for the wrong side of the ledger in a market where acquirers are shopping for trust, not capacity.

Where this leaves founders

None of this is a reason to build toward an acquisition as the end goal. It's a reason to be deliberate about which of the two businesses inside your company you're actually investing in.

Hexaura Solutions helps founders in health, wellness, and nutraceuticals validate demand, define positioning, and build go-to-market strategy before manufacturing decisions lock them in. If you're weighing where to invest (formulation, brand, or both) we'd be glad to talk it through.